Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease

Show full item record



Permalink

http://hdl.handle.net/10138/326986

Citation

Huoponen , S , Eberl , A , Räsänen , P , Roine , R P , Sipponen , T , Arkkila , P & Blom , M 2020 , ' Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease ' , Medicine (Baltimore) , vol. 99 , no. 2 , 18723 . https://doi.org/10.1097/MD.0000000000018723

Title: Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
Author: Huoponen, Saara; Eberl, Anja; Räsänen, Pirjo; Roine, Risto P.; Sipponen, Taina; Arkkila, Perttu; Blom, Marja
Contributor: University of Helsinki, Division of Pharmacology and Pharmacotherapy
University of Helsinki, University of Helsinki
University of Helsinki, HUS Helsinki and Uusimaa Hospital District
University of Helsinki, Faculty of Medicine
University of Helsinki, HUS Abdominal Center
University of Helsinki, HUS Abdominal Center
University of Helsinki, University of Helsinki
Date: 2020-01
Language: eng
Number of pages: 8
Belongs to series: Medicine (Baltimore)
ISSN: 0025-7974
URI: http://hdl.handle.net/10138/326986
Abstract: Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD patients. The objective of this study was to evaluate impact of switching originator to biosimilar IFX on HRQoL, disease activity, and health care costs in IBD maintenance treatment. In this single-center prospective observational study, all IBD patients receiving maintenance IFX therapy were switched to biosimilar IFX. HRQoL was measured using the generic 15D health-related quality of life instrument (15D) utility measurement and the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ). Crohn Disease Activity Index (CDAI) or Partial Mayo Score (pMayo), and fecal calprotectin (FC) served for evaluation of disease activity. Data were collected at time of switching and 3 and 12 months after switching. Patients' characteristics, clinical background information and costs were collected from patient records and the hospital's electronic database. Fifty-four patients were included in the analysis. No statistically significant changes were observed in 15D, CDAI, pMayo, and FC during 1-year follow-up. IBDQ scores were higher (P = .018) in Crohn disease 3 months after switching than at time of switching. Costs of biosimilar IFX were one-third of costs of originator one. Total costs related to secondary health care (excluding costs of IFX), were similar before and after the onset of biosimilar IFX. HRQoL and disease activity were after switching from originator to biosimilar IFX comparable, but the costs of biosimilar IFX were only one-third of those of the originator one.
Subject: biosimilar
Crohn disease
health-related quality of life
inflammatory bowel disease
infliximab
ulcerative colitis
DOUBLE-BLIND
INNOVATOR INFLIXIMAB
PARALLEL-GROUP
CT-P13
EFFICACY
15D
TONSILLECTOMY
MULTICENTER
DIAGNOSIS
SAFETY
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Health_related_quality_of_life_and_costs_of.78.pdf 395.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record